Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome .
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT00434304
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00422994
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00419692
- Locations
- 🇿🇦
GSK Investigational Site, George, South Africa
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
- Conditions
- Parkinson Disease
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 393
- Registration Number
- NCT00381472
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome (RLS)Restless Legs Syndrome
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 39
- Registration Number
- NCT00373542
- Locations
- 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Axxonis Pharma AG
- Target Recruit Count
- 300
- Registration Number
- NCT00367822
- Locations
- 🇩🇪
IMEREM GmbH, Nuremberg, Germany
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
- Conditions
- Restless Legs SyndromeRestless Legs Syndrome (RLS)
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT00363857
- Locations
- 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
- Conditions
- Parkinson's DiseaseDyskinesiasParkinson Disease
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT00363727
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
- Conditions
- Restless Legs SyndromeModerate to Severe Idiopathic Restless Legs Syndrome (RLS)
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00357097
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00355641
- Locations
- 🇨🇦
GSK Investigational Site, Regina, Saskatchewan, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.